Reimagining diversity in multiple myeloma clinical trials
Hematol Oncol
.
2022 Oct;40(4):689-694.
doi: 10.1002/hon.2997.
Epub 2022 Apr 13.
Authors
Dany Habr
1
,
Massimo Corsaro
2
Affiliations
1
Pfizer Oncology, Pfizer Inc., New York City, New York, USA.
2
Pfizer Oncology, Milan, Italy.
PMID:
35391496
PMCID:
PMC9790672
DOI:
10.1002/hon.2997
No abstract available
Keywords:
clinical trials; disparity; diversity; multiple myeloma.
MeSH terms
Humans
Multiple Myeloma* / drug therapy